[HTML][HTML] Zidovudine ameliorates pathology in the mouse model of Duchenne muscular dystrophy via P2RX7 purinoceptor antagonism

R Al-Khalidi, C Panicucci, P Cox, N Chira, J Róg… - Acta Neuropathologica …, 2018 - Springer
Duchenne muscular dystrophy (DMD) is the most common inherited muscle disorder that
causes severe disability and death of young men. This disease is characterized by …

[HTML][HTML] P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy

A Sinadinos, CNJ Young, R Al-Khalidi, A Teti… - PLoS …, 2015 - journals.plos.org
Background Duchenne muscular dystrophy (DMD) is the most common inherited muscle
disease, leading to severe disability and death in young men. Death is caused by the …

Therapeutic approaches for Duchenne muscular dystrophy

TC Roberts, MJA Wood, KE Davies - Nature Reviews Drug Discovery, 2023 - nature.com
Duchenne muscular dystrophy (DMD) is a monogenic muscle-wasting disorder and a
priority candidate for molecular and cellular therapeutics. Although rare, it is the most …

Dystrophin: The dead calm of a dogma

DC Górecki - Rare Diseases, 2016 - Taylor & Francis
Duchenne muscular dystrophy (DMD) is the most common inherited muscle disease leading
to severe disability and death of young men. Current interventions are palliative as no …

Mammalian models of Duchenne Muscular Dystrophy: pathological characteristics and therapeutic applications

A Nakamura, S Takeda - BioMed Research International, 2011 - Wiley Online Library
Duchenne muscular dystrophy (DMD) is a devastating X‐linked muscle disorder
characterized by muscle wasting which is caused by mutations in the DMD gene. The DMD …

Duchenne muscular dystrophy: pathogenesis and promising therapies

M Chang, Y Cai, Z Gao, X Chen, B Liu, C Zhang… - Journal of …, 2023 - Springer
Duchenne muscular dystrophy (DMD) is a severe, progressive, muscle-wasting disease,
characterized by progressive deterioration of skeletal muscle that causes rapid loss of …

Murine models of Duchenne muscular dystrophy: is there a best model?

K Swiderski, GS Lynch - American Journal of Physiology …, 2021 - journals.physiology.org
Duchenne muscular dystrophy (DMD) is a debilitating X-linked recessive skeletal muscle-
wasting disorder affecting 1 in 3,500–6,000 live-born males. Despite mutations in the dmd …

Impending therapies for Duchenne muscular dystrophy

TA Partridge - Current opinion in neurology, 2011 - journals.lww.com
Although genetic and cell-mediated approaches are currently showing genuine promise in
preclinical and clinical trials, there remains considerable interest in the development of …

Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials

JN Kornegay, CF Spurney, PP Nghiem… - ILAR …, 2014 - academic.oup.com
Duchenne muscular dystrophy (DMD) is an X-linked human disorder in which absence of
the protein dystrophin causes degeneration of skeletal and cardiac muscle. For the sake of …

Evolving therapeutic options for the treatment of duchenne muscular dystrophy

ES D'Ambrosio, JR Mendell - Neurotherapeutics, 2023 - Elsevier
Duchenne muscular dystrophy (DMD) is the most common childhood form of muscular
dystrophy. It is caused by mutations in the DMD gene, leading to reduced or absent …